NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
This newly launched institute will be the centre of excellence in the treatment of all cancers under a single roof.
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Expanding precision medicine, ARTIS icono is designed to enable a wide procedure mix in a single interventional suite
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala
He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
Subscribe To Our Newsletter & Stay Updated
